Here`s my Pick of the Week’s News as published by Multiple Sclerosis News Today. Fitness Trainer and MS Patient, Dolly Stokes, Launches BFitLifestyles Website with Husband Looking after what you eat and exercising according to your abilities apparently can help alleviate symptoms of many chronic illnesses including…

Canadian researchers are testing mice to see if cannabinoid oil products — a common medical marijuana treatment — could help alleviate the neuropathic pain that often afflicts patients with multiple sclerosis (MS). The preclinical study, “Identifying the molecular mechanisms involved in supressing multiple sclerosis induced neuropathic pain following cannabinoid treatment in…

Here’s my Pick of the Week’s News as published by Multiple Sclerosis News Today. MS Patients with Spasticity Needed for Study of Extended-release Baclofen Capsules Now here’s a rare chance to get involved in a clinical trial – as long as you have MS and experience some form…

Most Irish general practitioners (GPs) are against decriminalizing cannabis use, but many, especially those over age 50, say it can be useful for treating multiple sclerosis (MS) and other medical conditions, according to a recent survey. The results are detailed in the study, “Irish general practitioner attitudes toward decriminalisation…

Certain cannabinoids reduce spasticity symptoms in multiple sclerosis (MS) patients, according to a report  from the National Academies of Sciences, Engineering, and Medicine that scrutinized published research about the benefits and hazards of cannabis and cannabinoid use. Cannabinoids also show proven effect in other areas that may be important to MS patients, but they are linked…

Here is my Pick of the Week’s News as published by Multiple Sclerosis News Today. Effectiveness and Safety of DMDs Top Patient Concerns with These Therapies, Survey Says Having progressive multiple sclerosis, the issue of drugs that are disease modifying therapies (DMTs) has never arisen in my…

BAS Research, recently granted California’s first medicinal marijuana manufacturing and research license, is teaming with Montel Williams’ LenitivLabs startup to begin developing, producing and marketing medical-grade cannabis products. BAS’ goal is to replace the social stigma associated with cannabis by creating medical marijuana products with standardized dosing and proven efficacy. Its products are aimed at…

Voters in four U.S. states on Nov. 8 chose to legalize the recreational use of marijuana, and those in three other states approved the medicinal use of cannabis — all gains for pharmaceutical and other companies designing cannabis-based therapies for people with long-term chronic ills whose symptoms might be helped with these…

CannaCure Florida, a patient-focused producer of medical cannabis and related products, will host physicians and medical professionals for a peer-to-peer medical cannabis educational conference Nov. 18 in Tampa to provide guidance for incorporating medical cannabis into traditional medical practices. The event will be held 9 a.m. to 4:30 p.m. at the Cuban…

Abide Therapeutics announced that Celgene has opted to obtain the rights, outside of the United States, to ABX-1431, Abide’s endocannabinoid system modulator being developed to treat neurological diseases, including multiple sclerosis (MS), by reproducing within the body the physical benefits (minus the psychotropic effects) of cannabis. ABX-1431 is an…

Here’s my Pick of the Week’s News as published by Multiple Sclerosis News Today. #ECTRIMS2016 was undoubtedly the star of the week ECTRIMS, the European Committee for Treatment and Research in Multiple Sclerosis, dominated the news stories of the week when it held its 32nd congress in London. There…

Montel Williams, a Naval Academy graduate diagnosed with multiple sclerosis (MS) in 1999 , recently announced the launch of a line of high-quality medical cannabis products under the brand name LenitivLabs by Lenitiv Scientific. The former television host and wellness advocate has been particularly vocal when it comes to support the use of medical…

Earth Life Sciences (ELS), a venture capital and management firm based in Quebec, announced that it is partnering with a cannabis oil-based nutraceutical company, with an agreement in place to acquire that company and establish a new division. The resulting entity will be an organic medical marijuana oils (CBD) producer that will develop products…

Medical cannabis is subject to laws relating to the growing, possession, transport, and use of marijuana. These vary from country to country and, in the United States, from state to state. There are also differences between marijuana for general and recreational use and for the same product for medical use.

Barcelona, Spain-based, global pharma firm Almirall presented new clinical evidence at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) — held in Barcelona October 7–10, 2015 — supporting the efficacy of its Sativex product, currently the only pharmaceutical medicine derived from cannabinoids…

AXIM Biotechnologies, Inc. (AXIM)’s clinical trials testing a new pharmaceutical-grade cannabis chewing gum treatment option for Multiple Sclerosis (MS) pain and spasticity are drawing lots of popular and specialty media attention, with reports in Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money,…

AXIM Biotechnologies, Inc., a biotechnology company focused on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products derived from industrial hemp, has announced commencement of clinical development of its leading patented pharmaceutical chewing gum, MedChew RX, for registration as a drug for relieving pain and/or spasticity…

The 2012 and 2014 ballots approving legalization of cannabis in four U.S. states have stirred the pot, so to speak, on a wide range of issues and nuances related to the herb — not least marijuana’s clinical use as a therapeutic agent. Medical marijuana remains a topic of debate…

Welsh health minister Mark Drakeford has announced that Wales has become the first UK country to authorize a cannabis-based medicine under its National Health Service. Sativex, a proprietary oral spray cannabinoid medicine that has been licensed in the UK to treat muscle spasms and stiffness in people…

Nabiximols, the cannabis-based oral spray sold as Sativex, is available for reimbursement as an add-on therapy for moderate to severe spasticity in adults with multiple sclerosis (MS) in Ireland who failed to respond as intended to other spasticity medications. Marked by muscle stiffness and involuntary spasms or twitches,…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: A closer look at the EBV-MS link Much has been written over the past few years about the…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Good patient reviews for Sativex Sativex (nabiximols) is an oral cannabinoid spray designed to ease MS…

Real-world use of nabiximols, an oral spray cannabinoid treatment, was associated with a self-reported easing of spasticity and related symptoms for people with multiple sclerosis (MS), according to a recent study in Austria. Most patients (87.5%) said they were at least partly satisfied with the therapy — available…

A recent question on the MS News Today Facebook page generated some buzz about getting a buzz on to treat your multiple sclerosis (MS). The question was, “What helps you the most to manage your daily life with MS?” Many people with MS said the thing that helped…

Multiple Sclerosis News Today brought consistent coverage of the latest scientific research, developments in treatment, and clinical trials for multiple sclerosis (MS) throughout 2022. This is a list of the top 10 most-read articles we published this past year, with a brief description of each. We look forward…

Here are a few multiple sclerosis (MS) stories that caught my eye last week: Can nabiximols ease MS spasticity? In “4 Weeks of Nabiximols Found to Ease Spasticity in MS Pilot Study,” Margarida Maia reports some potentially good news for people with MS spasticity. Nabiximols, marketed in…

Four weeks of treatment with nabiximols — an oral spray containing compounds found in the cannabis plant — significantly reduced spasticity and generally improved arm and hand function in multiple sclerosis (MS) patients with moderate-to-severe spasticity, according to a small pilot study in Italy. Notably, after nabiximols, patients showed…

EHP-101, an experimental treatment being clinically tested for multiple sclerosis (MS), activates a cellular signaling pathway that promotes blood vessel development and reduces inflammation following brain injury, a new study shows. The findings continue to support the use of EHP-101 in MS, a condition marked by excess inflammation and…

It seems to me from my anecdotal observations that a fair number of people living with multiple sclerosis (MS) have a gun. When I wrote about the issue a few years ago, I discovered that more people than I expected had both a gun and MS. Additionally, many…

This news seems disappointing: A Phase 3 clinical trial of nabiximols — which is available under the brand name Sativex in several countries, including Canada and most of Europe — has failed to meet its primary goal of reducing leg spasticity in people with multiple sclerosis (MS). Nabiximols…